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Abstract 
Background 
Lifelong adherence with post-transplant immunosuppression is challenging, with nonadherence associated with 
greater acute rejection (AR) risk. 
Methods 
This retrospective study evaluated conversion from immediate-release tacrolimus (IRT) to prolonged-release 
tacrolimus (PRT), between January 2008 and December 2012 in stable adult heart transplant recipients. Cumulative 
incidence rate (IR) of AR and infection pre- and postconversion, safety, tacrolimus dose and trough levels, 
concomitant immunosuppression, and PRT discontinuation were analyzed (intention-to-treat population). 
Results 
Overall, 467 patients (mean age, 59.3 [SD, 13.3] years) converted to PRT at 5.1 (SD, 4.9) years post transplant 
and were followed for 3.4 (SD, 1.5) years. During the 6 months post conversion, 5 patients (1.1%; 95% CI, 0.35%–
2.48%) had an AR episode and IR was 2.2/100 patient-years (95% CI, 0.91–5.26). Incidence of rejection 
preconversion varied by time from transplant to conversion. Infection IR was similar post- and preconversion 
(9.2/100 patient-years [95% CI, 7.4–11.3] vs 10.6/100 patient-years [95% CI, 8.8–12.3], respectively; P = .20). Safety 
variables remained similar post conversion. The IR of mortality/graft loss was 2.3/100 patient-years (95% CI, 1.7–
3.1). 
Conclusions 
Conversion from IRT to PRT in heart transplant recipients in Spain was associated with no new safety concerns 
and appropriate immunosuppressive effectiveness. 
Tacrolimus is a well-established immunosuppressive agent for the prevention and treatment of 
allograft rejection. Two oral capsule formulations are currently available. Prolonged-release tacrolimus 
(PRT), available in Spain since 2007, is a once-daily formulation introduced as an alternative to twice-
daily, immediate-release tacrolimus (IRT). Previous studies have indicated that the area under the 
concentration–time curve of tacrolimus is approximately 10% lower following conversion from IRT to 
PRT in kidney, liver, and heart recipients [1], [2], [3], and dose adjustments may be required post 
conversion to achieve similar tacrolimus trough levels [4], [5], [6]. Simplifying transplant 
immunosuppressive regimens is desirable, as patient adherence to a lifelong treatment remains 
challenging. This may be because of complex treatment regimens with multiple tablets and different 
frequencies of administration in addition to adverse events (AEs). Nonadherence in transplant patients is 
especially important in the long term, where unsatisfactory outcomes are observed [7], [8], [9], [10]. 
Indeed, nonadherence is increasingly recognized as an important and scarcely reported cause of late acute 
rejection (AR), chronic rejection, and graft loss [8], [10], [11], [12], [13], [14], [15], [16], [17]. Recent 
studies of converting solid organ transplant recipients to PRT [18], [19], [20], [21] suggest that once-daily 
dosing improves adherence vs twice-daily dosing [18], [19], [20], [21], [22]. 
 
While many heart recipients in Spain have converted to PRT, the outcomes and safety of this 
conversion have not been evaluated. This retrospective observational study explored the conversion from 
IRT to PRT in the largest series of stable heart transplant patients to date, with the primary aim to analyze 
AR episodes and infections, which are associated with tacrolimus under- and overimmunosuppression, 
respectively [23]. A secondary aim was to explore the dose and trough levels of tacrolimus, and 
tolerability and safety after the conversion. 
 
Patients and Methods 
This multicenter, observational, retrospective study was carried out in 14 centers in Spain. The study 
was conducted according to the Declaration of Helsinki and was approved by the ethics committee of the 
University Hospital Marqués de Valdecilla (Santander, Spain). All current regulations for 
noninterventional studies, patient and data protection, and the specific policy of each center or 
administrative region were applied. All patients provided written informed consent for their data to be 
used. 
Patients and Procedures 
Adult patients (older than 18 years at the time of conversion) who had undergone heart transplant, 
received ≥6 months of continued treatment with IRT (Prograf®, Astellas Pharma Ltd, Chertsey, United 
Kingdom), and who underwent conversion to PRT (Advagraf®, Astellas Pharma Europe BV, Leiden, 
Netherlands) between January 2008 and December 2012 were eligible to participate in the study. Patients 
were followed up until June 2013; all study visits took place at the participating centers. All data were 
collected retrospectively from the centers’ registries in an electronic case report form. Data collection was 
performed by the investigator or the person delegated to act on their behalf. The procedures used for 
assuring data quality were consistent with those reported for the Spanish Heart Transplantation 
Registry [24]. 
 
Tacrolimus daily dose and serum trough levels, concomitant immunosuppression, concomitant 
medication, laboratory evaluation, and graft function were recorded at 6 months preconversion, at the 
time of conversion, and at 1, 6, 12, 24, 36, and 48 months post conversion. Occurrence of AR and 
infections was recorded from 2 years preconversion to the end of follow-up. Incidence and reasons for 
PRT discontinuation were recorded over the follow-up period. 
Variables and Endpoints 
No common strategy or specific protocol for rejection surveillance following PRT conversion was 
used across participating centers. The primary endpoint was the cumulative incidence rate (IR) of AR at 6 
months post conversion from IRT to PRT, defined as any episode of rejection determined by clinical 
suspicion, echocardiogram, or biopsy that caused an intensification of immunosuppressive treatment. AR 
episodes separated by ≥15 days after the treatment of the preceding event were considered independent, 
in line with recommendations from the Spanish Heart Transplant Groups Consensus Conference [25]. 
 
Secondary variables, including the incidence of biopsy-confirmed AR and infection, were compared 
before and after conversion from IRT to PRT. Infection was defined as any episode requiring intravenous 
antibiotic therapy, hospital admission, or specific therapy for opportunistic infections (eg, tuberculosis). 
Safety analyses included the incidence of diabetes, and renal dysfunction–as renal dysfunction has been 
associated with the use of calcineurin inhibitors [26] and post-transplant diabetes mellitus has been 
reported in patients receiving tacrolimus-based immunosuppression [27], [28]. Renal dysfunction was 
defined as a 25% increase in serum creatinine at 2 consecutive determinations, in line with current 
consensus for the decrease in estimated glomerular filtration rate used to define chronic renal 
disease [29]. It was considered that an increase of <25% may be due to physiological variations in serum 
creatinine levels. At the end of the follow-up period, patient and graft survival, and biopsy-confirmed AR, 
were also analyzed. 
  
Statistical Procedures 
No formal sample size calculation was performed. Continuous variables are summarized as mean 
(SD). Categorical variables are described as percentages. 
 
Differences in pre- and postconversion occurrence of AR and infection were assessed by comparing 
their respective IRs (number of episodes per 100 patient-years on treatment) and by comparing the IR 
ratio using the preconversion period as reference. Because the incidence of rejection is influenced by the 
time elapsed since transplant, differences between pre- and postconversion periods were analyzed in the 
whole study group and separately in 3 patient subsets according to time from transplant to conversion 
(<2, 2–4, and ≥4 years). 
 
Significance level was established at P < .05, with no adjustment for multiplicity. The statistical 
package SPSS 17.0 (SPSS Inc., Chicago, Illinois) was used. 
Results 
Overall, 467 heart recipients met eligibility criteria and were included in the study, and none were lost to 
follow-up; demographic and clinical characteristics are summarized in Table 1. The mean time from 
transplant to conversion was 5.1 (SD, 4.9) years. Conversion from IRT to PRT was carried out <2 years 
post transplant in 119 patients (25.5%), between 2 and 4 years in 82 patients (17.6%), and ≥4 years after 
transplant in 266 patients (57.0%). Patients were followed up after conversion for a mean of 3.4 (SD, 1.5) 
years. 
  





Age, mean (SD), y 59.3 (13.3) 
Sex, male/female, % 68.5/31.5 
Primary diagnosis of cardiopathy, %  
 Dilated 71.7 
 Ischemic 7.7 
 Others 20.6 
Weight at baseline, mean (SD), kg 70.1 (14.5) 
CMV serology positive, % 79.0 
Hypertension (n = 454), % 60.4 
Diabetes (n = 454), % 29.1 
Cerebrovascular accident, % 8.1 
Malignant neoplasm (n = 32), %  
 Cutaneous 56.3 
 Lymphoproliferative 12.5 
 Solid organ 34.4 
History of heart failure, % 7.7 
Cardiac allograft vasculopathy, % 11.6 
Cardiac rhythm (conversion visit) (n = 463), %  
 Sinus rhythm 96.1 
 Atrial fibrillation 0.6 
 Pacemaker 1.7 
 Other 1.5 
Time from transplant to conversion, mean (SD), y 5.1 (4.9) 
Conversion time post transplant, No. (%)  
 <2 y 119 (25.5) 
 2–4 y 82 (17.6) 
 ≥4 y 266 (57.0) 
Donor age (n = 466), mean (SD), y 34.7 (12.8) 
Donor sex, male/female (n = 467), % 65.7/34.3 
 
Abbrevation: CMV, cytomegalovirus. 
 
Tacrolimus Daily Dose and Serum Trough Levels 
The mean doses of IRT immediately preconversion and the initial dose of PRT at conversion were 
3.84 (SD, 2.54) mg/d and 3.97 (SD, 2.57) mg/d, respectively (P = .27). Compared with preconversion 
values on IRT, mean PRT daily dose remained steady after 2 years had elapsed post conversion (Fig 1A). 
Mean tacrolimus trough level (preconversion) with IRT (8.93 [SD, 3.49] ng/mL) declined 1 month after 
conversion to PRT (7.86 [SD, 2.86] ng/mL), and was 7.70 (SD, 2.91) ng/mL and 6.95 (SD, 2.53) ng/mL 
at months 6 and 48, respectively (Fig 1B). During the 48-month follow-up period, serum levels of PRT 
decreased significantly vs preconversion levels (P < .01). 




Fig 1. (A) Mean (SD) daily dose and (B) mean (SD) serum trough levels of tacrolimus over the study period for all patients. 




Concomitant immunosuppression use is summarized in Table 2. The proportion of patients using 
mycophenolate mofetil and prednisone decreased between month 1 and month 48 post conversion. Use of 
mammalian target of rapamycin inhibitors (largely everolimus and not sirolimus) increased approximately 
2-fold during follow-up. 
Table 2. Concomitant Immunosuppression Use in All Patients Defined According to Time From Conversion to Prolonged-Release 
Tacrolimus 
 
Immunosuppressive Agent, % Conversion 
Visit∗ 
6 Mo  
(n = 432) 
12 Mo  
(n = 434) 
24 Mo  
(n = 401) 
36 Mo  
(n = 341) 
48 Mo 
 (n = 261) 
MMF 76.6 73.4 71.0 69.0 67.3 65.9 
Mycophenolic acid 7.0 7.7 8.3 8.0 9.1 10.7 
Prednisone 58.6 56.2 54.1 51.1 50.7 49.4 
Azathioprine 5.4 5.1 5.1 5.0 5.3 4.6 
Sirolimus 1.1 1.2 1.1 1.2 1.2 0.8 
Everolimus 6.4 7.9 10.2 11.7 12.9 13.5 
 
Information on immunosuppressive agent use in all patients was not available; therefore, denominators vary (n). 
Abbreviation: MMF, mycophenolate mofetil. 
*Because of missing data, n is: MMF, n = 461; mycophenolic acid, n = 444; prednisone, n = 454; azathioprine, n = 441; sirolimus, 
n = 438; everolimus, n = 437. 
Rejection and Infection 
During the 6 months post conversion, 5 patients (1.1%; 95% CI, 0.35%–2.48%) had an AR episode. 
The time-adjusted IR of AR 6 months after conversion was 2.19 (95% CI, 0.91–5.26) AR events per 100 
patient-years, with a cumulative follow-up of 228.35 patient-years. 
 
In the 2 years before conversion (837.68 patient-years), there were 68 episodes of rejection in 48 
patients. Thus, 10.3% of patients had at least 1 rejection episode preconversion, with most (79.2%) of 
these patients experiencing 1 event. 
 
In the 2 years post conversion, with a cumulative follow-up of 891.56 patient-years, there were 18 
rejection episodes. Fifteen patients (3.2%) presented with at least 1 rejection episode; 12 of these patients 
had 1 rejection episode, and 3 patients had 2 rejections. The 2-year preconversion rejection IR was 8.1 per 
100 patient-years (95% CI, 6.4–10.3), and was 2.0 per 100 patient-years (95% CI, 1.3–3.2) in the 2-year 
postconversion period (P < .0001) (Fig 2A). Therefore, the IR ratio of rejection (2 years post 
conversion:2 years preconversion) was 0.25 (95% CI, 0.14–0.42). This overall decrease was largely due 
to the decline in rejection IR among patients converted <4 years post transplant, with no significant 





Fig 2. (A) Pre- and postconversion incidence rates of rejection for all patients and (B) incidence rate ratio (post- to preconversion) of 
rejection split by time from transplant to conversion from immediate- to prolonged-release tacrolimus (<2, 2–4, and ≥4 years). Bars 
represent the upper and lower limits of the CI. IRT, immediate-release tacrolimus 
In the 2 years before conversion, 16 (23.5%), 50 (73.5%), and 15 (22.1%) rejection episodes were 
diagnosed based on clinical suspicion, biopsy, and echocardiogram, respectively (rejections could be 
diagnosed by more than 1 method). In the 2 years post conversion, of the 18 rejection episodes, 16 
(88.9%), 15 (83.3%), and 11 (61.1%) were diagnosed based on clinical suspicion, biopsy, and 
echocardiogram, respectively. Compared with the 2-year preconversion period, the 2-year postconversion 
period showed a trend toward a higher likelihood of a rejection diagnosis being made by biopsy (73.5% 
vs 83.3%), a higher proportion of rejection episodes with hemodynamic compromise (10.3% [n = 7] vs 
25.0% [n = 4]), and a higher proportion of cytolytic therapy usage (4.4% [n = 3] vs 11.1% [n = 2]). 
 
Overall, there were 99 infection episodes in 82 patients in the 2 years preconversion (infection rate 
17.6%; IR, 10.6 per 100 patient-years; 95% CI, 8.8–12.3) and 82 infections in 67 patients in the 2-year 
postconversion period (IR, 9.2 per 100 patient-years; 95% CI, 7.4–11.3). The difference between the 
postconversion and preconversion IR was not statistically significant (IR ratio, 0.87; 95% CI, 0.64–
1.17; P = .17) (Fig 3). During the pre- and postconversion periods, most infection episodes required 




Fig 3. Pre- and postconversion incidence rates of infection for all patients. Bars represent the upper and lower limits of the CI. IRT, 
immediate-release tacrolimus. 
Safety Evaluation 
Key safety findings among patients converted to PRT are summarized in Table 3. There were 
increases in leukocytes, hemoglobin, total cholesterol, low-density lipoprotein cholesterol, body weight, 
systolic and diastolic blood pressure, and the prevalence of nonsinus rhythm during follow-up. Cardiac 
and renal function, assessed by left ventricular ejection fraction and serum creatinine levels, respectively, 
remained stable, and there was a decrease in glomerular filtration rate. The trends in safety parameters 
were not considered clinically relevant. Between month 1 and month 24 post conversion, 6.5% of patients 
experienced renal dysfunction. The proportion of patients with diabetes in the preconversion period and 
48 months post conversion was similar (29.1% and 31.5%, respectively). 
 
PRT was discontinued in 33 patients (7.1%), who could have more than 1 reason for discontinuation; 
in approximately half of cases (n = 15, 3.2% of the total study population), AEs were the reason for 
treatment discontinuation. Other reasons for discontinuation included implementation of a calcineurin 
inhibitor-free regimen because of malignancy (8 patients, 1.7%), patients’ refusal to take PRT (5 patients; 
1.1%), inadequate tacrolimus serum trough levels (2 patients; 0.4%), renal failure (2 patients; 0.4%), AR 
(1 patient; 0.2%), and physician’s refusal to administer PRT (1 patient; 0.2%). 
 
There were 34 deaths (7.3%) by the end of follow-up. Causes of death were malignancy (10 patients; 
2.1%), graft vascular disease (6 patients; 1.3%), sudden death (6 patients; 1.3%), AR (4 patients; 0.9%), 
infection (1 patient; 0.2%), and “other” (7 patients; 1.5%). The IR of mortality/graft loss was 2.3 per 100 
patient-years (95% CI, 1.7–3.1). 
  
Table 3. Safety Parameters in Patients Converted to Prolonged-Release Tacrolimus (N = 467) 
Parameter Preconversion 6 Mo 12 Mo 24 Mo 36 Mo 48 Mo 
Leukocytes, × 103 7.2 (2.3) 7.4 (2.1) 7.5 (2.2) 7.4 (2.4) 7.4 (2.2) 7.3 (2.1) 
Hemoglobin, g/dL 13.4 (1.8) 13.6 (1.7) 13.7 (1.7) 13.7 (1.7) 13.7 (1.8) 13.8 (1.7) 
Platelets, × 103 211.5 (67.7) 209.2 (61.9) 211.0 (61.9) 205.7 (61.8) 207.2 (64.8) 208.4 (67.8) 
Fasting glycemia, mg/dL 106.4 (38.9) 107.4 (41.3) 107.7 (37.1) 106.61 (33.1) 106.5 (31.4) 107.1 (37.3) 
Insulin therapy, % 18.0 18.8 18.9 17.2 18.8 18.8 
Serum creatinine, mg/dL 1.28 (0.61) 1.26 (0.62) 1.24 (0.62) 1.27 (0.61) 1.27 (0.52) 1.27 (0.56) 
GFR, mL/min/1.73 m2 71.9 (25.2) 66.4 (23.8) 67.5 (23.6) 73.3 (26.2) 65.9 (25.1) 65.7 (24.6) 
Total cholesterol, mg/dL 168.4 (35.2) 172.4 (34.6) 174.4 (35.5) 175.3 (35.9) 173.6 (35.7) 173.3 (34.2) 
HDL cholesterol, mg/dL 52.4 (15.6) 52.4 (15.6) 53.6 (15.2) 55.1 (15.9) 53.6 (15.5) 54.6 (17.2) 
LDL cholesterol, mg/dL 91.0 (28.5) 94.7 (28.5) 94.6 (26.8) 94.3 (28.9) 95.2 (26.3) 94.7 (25.8) 
Triglycerides, mg/dL 131.1 (82.2) 128.2 (82.2) 133.4 (95.1) 129.3 (69.3) 126.2 (64.2) 125.8 (63.6) 
AST, U/L 23.5 (15.7) 23.5 (15.7) 22.7 (16.9) 21.9 (13.8) 23.4 (18.2) 22.9 (16.6) 
ALT, U/L 23.1 (18.6) 23.1 (18.6) 21.3 (14.9) 21.2 (14.4) 22.2 (18.6) 22.7 (17.7) 
Weight, kg 74.7 (15.9) 74.7 (16.0) 75.6 (16.4) 76.3 (16.4) 76.2 (16.5) 76.3 (16.3) 
Systolic blood pressure, mm Hg 128.7 (16.7) 128.7 (16.7) 129.7 (16.5) 132.1 (16.4) 132.0 (18.4) 133.0 (17.4) 
Diastolic blood pressure, mm Hg 81.1 (10.7) 81.1 (10.7) 81.9 (10.6) 83.7 (11.9) 83.3 (11.8) 83.9 (11.9) 
Heart rate, bpm 88.8 (13.9) 88.8 (13.9) 88.0 (13.5) 87.9 (14.0) 88.6 (13.9) 88.2 (13.3) 
Nonsinus rhythm, % 3.9 3.9 5.5 5.0 6.2 7.7 
Left ventricle ejection fraction, % 63.8 64.6 64.8 64.8 64.1 64.45 
 
Data are mean (SD) unless otherwise stated. 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; bpm, beats per minute; GFR, glomerular filtration 
rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein. 
Discussion 
To date, a small number of studies have explored the use of PRT immunosuppression in heart 
transplant recipients. As these studies were small [5] or focused on pharmacokinetics and drug 
dosage [1], [4], data on the characteristics and results of tacrolimus conversion in cardiac recipients have 
not been described. Our results from this large multicenter study suggested that the rate of infection 
remained similar before and after conversion from IRT to PRT. The incidence of AR was lower during 
the 48 months of follow-up post conversion from IRT to PRT compared with the rates within 2 years 
preconversion. However, the time since transplant was not accounted for in analyses of the overall cohort. 
Therefore, comparisons of rejection IR between pre- and post conversion should be interpreted with 
caution. Indeed, after stratifying our results by time between transplant and conversion, the decrease in 
rejection IR was largely due to the decline in rejection IR among patients converted <4 years post 
transplant, with no significant changes in those patients converted beyond 4 years post transplant. As 
such, the reduction in rejection rates post conversion may be due to greater time elapsed since transplant 
than to a true positive effect of the conversion. Additionally, it is likely that the frequency of routine 
biopsy surveillance was lower post- vs preconversion, and that postconversion rejection episodes were 
diagnosed on the basis of clinical suspicion and were confirmed by biopsy findings. Indeed, the frequency 
of diagnosis of rejection episodes based on clinical suspicion was substantially higher post conversion 
(88.9%) vs preconversion (23.5%). Interestingly, compared with the 2-year preconversion period, during 
all study follow-up there was a higher proportion of rejection episodes with hemodynamic compromise, 
although the cause for this is unclear. 
 
In our study, the PRT daily dose used at conversion was only 0.13 mg higher than that used for IRT. 
Mean tacrolimus trough levels are approximately 10% lower immediately post conversion from IRT to 
PRT on a 1mg:1mg total daily dose basis [1], [2], [3], and the reduction in trough levels may be greater in 
individual patients [2]. However, the maintenance of target tacrolimus levels is manageable via trough 
level monitoring and dose adjustment [30]. Studies have shown that approximately 10% of kidney and 
liver transplant patients converted from IRT to PRT on a 1mg:1mg total daily dose basis may require 
tacrolimus dose adjustment [31], [32]. In heart transplant patients, after conversion from IRT to PRT on 
day 8, Alloway et al reported an increase of approximately 10% in tacrolimus dose by day 35 to achieve 
tacrolimus trough levels within the range of 5 to 15 ng/mL [2]. Marzoa-Rivas et al report that a 25% 
increase in daily dose may be required to achieve the appropriate trough levels immediately after 
conversion from IRT to PRT in heart transplant recipients [4]. Accordingly, in a recent study of heart 
transplant patients receiving de novo PRT or IRT, a significantly higher daily dose of PRT was required 
to provide similar trough levels to IRT [6]. In our study, the trough level achieved with a mean IRT dose 
of 3.84 mg/d was higher than that achieved with a similar dose of PRT, which is consistent with other 
reports. However, the levels determined during the 48 months of follow-up, with the steady dose 
reduction, were within target [30]. 
 
The tacrolimus trough levels achieved with PRT in our study were sufficient (with concomitant 
immunosuppressive agents) to avoid AR. We did not observe the previously reported substantial 
progressive reduction in serum tacrolimus trough levels in patients receiving PRT de novo [5], [6]. Our 
results are more consistent with those of van Hooff et al, who found that tacrolimus trough concentrations 
were generally maintained at a stable level during 4 years of follow-up in heart transplant patients who 
converted to PRT, while doses were slightly reduced [33]. In our study, doses and serum trough levels 
maintained almost parallel curves during follow-up, which suggests good adherence to PRT. 
 
Biochemical parameters indicate a comparable safety profile between IRT and PRT in our study, 
which is consistent with other reports showing similar renal function, blood cell counts, liver function 
tests [1], [3], [4], [6], [18], [34], left ventricular function [6], and glycemia [4] between the formulations. 
Although there were changes in several parameters, including blood cell counts, lipid levels, body weight, 
and blood pressure, these trends were not considered to be clinically relevant. Regarding comorbidities 
and the safety of conversion to PRT in our study, follow-up data did not reveal substantial changes over 
time between the formulations or compared with baseline. For instance, serum glucose levels and the 
proportion of patients with insulin-dependent diabetes remained similar throughout the study. 
 
Conversion from IRT to PRT was generally well tolerated, as shown by the low dropout rate. There 
were 33 patients who discontinued PRT, with AEs the cause in approximately half of cases. The 
incidence of AEs with PRT administration in a 4-year period is high, according to previous trials [33], but 
this aspect was not closely monitored in our study. Van Hooff et al found that the incidence of AEs 
decreased over the 4-year follow-up, with infections, metabolic and nutrition disorders, and neoplasms 
being the most commonly-reported events among heart transplant recipients [33]. Of note, in this study, 
most infections (>80%) required hospitalization. This may be related to the challenge of tracking milder 
infections, for which patients may see their family physician or which may not be well documented in 
outpatient notes. 
 
There were some limitations to the study analyses. For example, observations were not independent, 
and only patients that converted were analyzed. It is likely that only patients with clinically stable 
tacrolimus dose and trough levels were converted, and, therefore, results may not apply to less clinically 
stable patients. Furthermore, competing risks (death and graft loss) and time since transplant may not 
have been sufficiently controlled. As such, there may be bias in the analyses herein, which could affect 
interpretation of the data. Additionally, comparing the overall IR for AR pre- vs post conversion could be 
affected by decreases in the risk of AR with time post transplant. There were also no controls for the 
different factors that may have contributed to the incidence of AR, such as nonadherence with 
immunosuppressive medication and concomitant immunosuppressive use. However, as concomitant 
immunosuppressive use was generally similar pre- and post conversion, it is unlikely to have strongly 
impacted the incidence of AR. The retrospective nature of the study also makes it difficult to explain the 
trend toward a higher likelihood of a rejection diagnosis being made by biopsy and the increase in 
rejection with hemodynamic compromise post vs preconversion to PRT, and patterns in cytolytic therapy 




In summary, this study provides valuable information about tacrolimus dosing, trough levels, and 
clinical effectiveness associated with the conversion of stable heart transplant recipients from IRT to PRT 
in clinical practice. The long-term experience reported here suggests that conversion from IRT to PRT in 
stable heart transplant recipients is accompanied by appropriate immunosuppressive effectiveness, 
adequate tolerability, and no new safety concerns. Moreover, PRT offers a more convenient dosing 
regimen that may have an impact on adherence, possibly influencing effectiveness, since enhanced 
adherence may yield improvements in long-term graft survival. 
Acknowledgments 
This study was sponsored by Astellas Pharma. The authors thank Dr Blanca Piedrafita, Medical 
Writer at Medical Statistics Consulting (Valencia, Spain), for her assistance with the manuscript. Editorial 
assistance was also provided by Daniella T Draper, PhD, CMPP, from Cello Health MedErgy (Europe), 
funded by Astellas Pharma, Inc. 
Data Statement 
Access to anonymized individual participant level data will not be provided for this trial as it meets 1 
or more of the exceptions described on www.clinicalstudydatarequest.com under “Sponsor Specific 
Details for Astellas.” 
References 
1. R. Alloway, S. Steinberg, K. Khalil, S. Gourishankar, J. Miller, D. Norman, et al.Conversion 
of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily 
modified release tacrolimus-based regimen 
Transplant Proc, 37 (2005), pp. 867-870 
2. R. Alloway, J. Vanhaecke, N. Yonan, M. White, H. Haddad, G. Rábago, et al. 
Pharmacokinetics in stable heart transplant recipients after conversion from twice-daily to 
once-daily tacrolimus formulations 
J Heart Lung Transplant, 30 (2011), pp. 1003-1010 
3. S. Florman, R. Alloway, M. Kalayoglu, K. Lake, T. Bak, A. Klein, et al. 
Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a 
once-daily modified release tacrolimus-based regimen 
Transplant Proc, 37 (2005), pp. 1211-1213 
4. R. Marzoa-Rivas, M.J. Paniagua-Martín, E. Barge-Caballero, V. Pedrosa del Moral, G. Barge-
Caballero, Z. Grille-Cancela, et al. 
Conversion of heart transplant patients from standard to sustained-release tacrolimus requires 
a dosage increase 
Transplant Proc, 42 (2010), pp. 2994-2996 
5. U. Fuchs, A. Zittermann, S. Ensminger, B. Schulze, K. Hakim-Meibodi, J. Gummert, et al. 
Clinical outcome in cardiac transplant recipients receiving tacrolimus retard 
Transplant Proc, 45 (2013), pp. 2000-2004 
6. F. González-Vílchez, J.L. Lambert, D. Rangel, L. Almenar, J.L. de la Fuente, J. Palomo, et al. 
Efficacy and safety of de novo and early use of extended-release tacrolimus in heart 
transplantation 
Rev Esp Cardiol (Engl Ed), 71 (2018), pp. 18-25 
7. K. Laederach-Hofmann, B. Bunzel 
Noncompliance in organ transplant recipients: a literature review 
Gen Hosp Psychiatry, 22 (2000), pp. 412-424 
8. S. De Geest, F. Dobbels, C. Fluri, W. Paris, T. Troosters 
Adherence to the therapeutic regimen in heart, lung, and heart-lung transplant recipients 
J Cardiovasc Nurs, 20 (2005), pp. S88-98 
9. A.F. Williams, E. Manias, C.J. Gaskin, K. Crawford 
Medicine non-adherence in kidney transplantation 
J Ren Care, 40 (2014), pp. 107-116 
 
 
10. F. Dobbels, S. De Geest, J. van Cleemput, W. Droogne, J. Vanhaecke 
Effect of late medication non-compliance on outcome after heart transplantation: a 5-year 
follow-up 
J Heart Lung Transplant, 23 (2004), pp. 1245-1251 
11. K. Denhaerynck, F. Dobbels, I. Cleemput, A. Desmyttere, P. Schäfer-Keller, S. Schaub, et al. 
Prevalence, consequences, and determinants of nonadherence in adult renal transplant 
patients: a literature review. 
Transpl Int, 18 (2005), pp. 1121-1133 
12. R.S. Gaston, S.L. Hudson, M. Ward, P. Jones, R. Macon 
Late renal allograft loss: noncompliance masquerading as chronic rejection 
Transplant Proc, 31 (1999), pp. 21S-23S 
13. R.E. O’Carroll, L.M. Mcgregor, V. Swanson, G. Masterton, P.C. Hayes 
Adherence to medication after liver transplantation in Scotland: a pilot study 
Liver Transpl, 12 (2006), pp. 1862-1868 
14. J.A. Butler, P. Roderick, M. Mullee, J.C. Mason, R.C. Peveler 
Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a 
systematic review 
Transplantation, 77 (2004), pp. 769-776 
15. M.A. Dew, R.L. Kormos, L.H. Roth, S. Murali, A. DiMartini, B.P. Griffith 
Early post-transplant medical compliance and mental health predict physical morbidity and 
mortality one to 3 years after heart transplantation 
J Heart Lung Transplant, 18 (1999), pp. 549-562 
16. J. Sellarés, D.G. de Freitas, M. Mengel, J. Reeve, G. Einecke, B. Sis, et al. 
Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated 
rejection and nonadherence 
Am J Transplant, 12 (2012), pp. 388-399 
17. H. Vlaminck, B. Maes, G. Evers, G. Verbeke, E. Lerut, B. Van Damme, et al. 
Prospective study on late consequences of subclinical non-compliance with 
immunosuppressive therapy in renal transplant patients 
Am J Transplant, 4 (2004), pp. 1509-1513 
18. S. Beckebaum, S. Iacob, D. Sweid, G.C. Sotiropoulos, F. Saner, G. Kaiser, et al. 
Efficacy, safety, and immunosuppressant adherence in stable liver transplant patients 
converted from a twice-daily tacrolimus-based regimen to once-daily tacrolimus extended-
release formulation 
Transpl Int, 24 (2011), pp. 666-675 
19. A.O. Doesch, S. Mueller, M. Konstandin, S. Celik, C. Erbel, A. Kristen, et al. 
Increased adherence after switch from twice daily calcineurin inhibitor based treatment to 
once daily modified released tacrolimus in heart transplantation: a pre-experimental study 
Transplant Proc, 42 (2010), pp. 4238-4242 
20. M. Eberlin, G. Otto, I. Krämer 
Increased medication compliance of liver transplant patients switched from a twice-daily to a 
once-daily tacrolimus-based immunosuppressive regimen 
Transplant Proc, 45 (2013), pp. 2314-2320 
21. D.R. Kuypers, P.C. Peeters, J.J. Sennesael, M.N. Kianda, B. Vrijens, P. Kristanto, et al. 
Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized 
controlled trial using electronic monitoring 
Transplantation, 95 (2013), pp. 333-340 
22. N. Weiler, I. Thrun, M. Eberlin, D. Foltys, M. Heise, M. Hoppe-Lotichius, et al. 
Tacrolimus effects and side effects after liver transplantation: is there a difference between 
immediate and extended release? 
Transplant Proc, 45 (2013), pp. 2321-2325 
23.  C. Söderlund, G. Rådegran 
Immunosuppressive therapies after heart transplantation – the balance between under- and 
over-immunosuppression 
Transplant Rev (Orlando), 29 (2015), pp. 181-189 
24. F. González-Vílchez, M. Gómez-Bueno, L. Almenar-Bonet, M.G. Crespo-Leiro, J.M. Arizón 
Del Prado, J. Delgado-Jiménez, et al. 
Spanish Heart Transplant Registry. 28th Official Report of the Spanish Society of Cardiology 
Working Group on Heart Failure (1984–2016) 
Rev Esp Cardiol (Engl Ed), 70 (2017), pp. 1098-1109 
25. M.G. Crespo Leiro, L.A. Bonet, L. Alonso-Pulpón, M. Campreciós, J.J. Cuenca Castillo, L. 
de la Fuente Galván, et al. 
Consensus Conference of Spanish Groups of Cardiac Transplantation 
Rev Esp Cardiol Supl, 7 (2007), pp. 4-54 
 
 
26. M. Naesens, D.R. Kuypers, M. Sarwal 
Calcineurin inhibitor nephrotoxicity 
Clin J Am Soc Nephrol, 4 (2009), pp. 481-508 
 
 
27. E.L. Porrini, J.M. Díaz, F. Moreso, P.I. Delgado Mallén, I. Silva Torres, M. Ibernon, et al. 
Clinical evolution of post-transplant diabetes mellitus 
Nephrol Dial Transplant, 31 (2016), pp. 495-505 
28. G. Mourad, M. Glyda, L. Albano, O. Viklický, P. Merville, G. Tydén, et al. 
Incidence of posttransplantation diabetes mellitus in de novo kidney transplant recipients 
receiving prolonged-release tacrolimus-based immunosuppression with 2 different 
corticosteroid minimization strategies: ADVANCE, a randomized controlled trial 
Transplantation, 101 (2017), pp. 1924-1934 
29. A. Martínez-Castelao, J.L. Górriz, J. Bover, J. Segura-de la Morena, J. Cebollada, J. Escalada, 
et al. 
Consensus document for the detection and management of chronic kidney disease 
Aten Primaria, 46 (2014), pp. 501-519 
30. Astellas Pharma Europe Ltd 
Advagraf 0.5mg, 1mg, 3mg and 5mg prolonged-release hard capsules summary of product 
characteristics 
(2015) 
31. L.M. Marin-Gomez, M.A. Gomez-Bravo, J.A. Alamo-Martinez, L. Barrera-Pulido, C. Bernal 
Bellido, G. Suárez Artacho, et al. 
Evaluation of clinical safety of conversion to Advagraf therapy in liver transplant recipients: 
observational study 
Transplant Proc, 41 (2009), pp. 2184-2186 
32.  B. Diez Ojea, M. Alonso Alvarez, S. Aguado Fernández, M. Baños Gallardo, S. García 
Melendreras, E. Gómez Huertas 
Three-month experience with tacrolimus once-daily regimen in stable renal allografts 
Transplant Proc, 41 (2009), pp. 2323-2325 
33. J.P. van Hooff, R.R. Alloway, P. Trunečka, M. Mourad 
Four-year experience with tacrolimus once-daily prolonged release in patients from phase II 
conversion and de novo kidney, liver, and heart studies 
Clin Transplant, 25 (2011), pp. 1-12 
34. S. Nunoda, K. Suwa, K. Shitakura, T. Kikuchi, S. Nakajima, M. Hattammaru, et al. 
Switching to tacrolimus extended-release improved the effectiveness of immunosuppressive 
therapy in a heart transplant patient: a case report 
J Cardiol Cases, 6 (2012), pp. e26-e29 
